OmniAb initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis initiated coverage of OmniAb with a Buy rating and $11 price target. The analyst says the company has the ondustry’s only four-species antibody discovery platform. OmniAb is a tools and technology platform company with ongoing and upcoming collaboration deals providing attractive and anticipated growth in revenue, the analyst tells investors in a research note.